Loading clinical trials...
Loading clinical trials...
Single-center, Open-Label, Non-randomized, Single-Arm Phase 1 Study to Evaluate the Safety and Tolerability of Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Conditions
Interventions
Dual CD33/CLL1 CAR T
Locations
1
China
Beijing Boren Hospital
Beijing, Beijing Municipality, China
Start Date
February 16, 2022
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2023
Last Updated
June 11, 2025
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06484062
NCT06994676
Lead Sponsor
Beijing Boren Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions